论文部分内容阅读
(智能手机、智能机器人、智能驾驶越来越成为我们日常生活中的焦点话题,而智能药物也正渐行渐近。)20多家公司正在争相开发一种数字技术来实时跟踪患者——监控他们的生命体征,提醒他们服药,甚至根据需要释放药物到他们体内。研究成功的回报将是双重的:潜在的巨大利润,以及由此获得的值钱的个人信息。初创公司普罗透斯数字健康(Proteus Digital Health)和日本的大冢制药(Otsuka Pharmaceutical)是两家致力于推动研发这种技术的代表公司。他们一起致力于寻求将微芯片植入阿立哌唑——一种抗抑郁和抗精神疾病的药物的注册审批。伴随着药片在胃里的溶解,跟踪镁和锌的数量电路组被激活,它向绑在腹部的绷带一样的传感器发送信息。
(Smartphones, smart robots, smart driving are increasingly the focus of our daily lives, and smart drugs are getting closer.) More than 20 companies are scrambling to develop a digital technology to track patients in real time - Monitor their vital signs, remind them to take their medication, and even release the medication into their body as needed. The return on research success will be twofold: the potential for huge profits, and the resulting valuable personal information. Startup companies Proteus Digital Health and Japan’s Otsuka Pharmaceutical are two representative companies dedicated to driving this technology. Together, they are working to find a microchip for aripiprazole, a drug that registers antidepressants and antipsychotics. As the tablets dissolve in the stomach, the track circuit of magnesium and zinc tracks is activated, sending a message to a bandage-like sensor tied to the abdomen.